Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
News|Articles|June 21, 2022
Sustainable Medicines Packaging Award Winners to be Announced at Connect in Pharma
Author(s)Pharmaceutical Technology Editors
Connect in Pharma will host an awards ceremony to showcase innovations in sustainable pharmaceutical packaging.
Advertisement
YewMaker and Connect in Pharma have announced that the winners of the new Sustainable Medicines Packaging Award will be announced at an in-person awards ceremony at the Connect in Pharma event in Geneva on Sept. 14, 2022.
The new awards are run by YewMaker, a sustainable healthcare company. The awards will highlight and celebrate sustainable innovations in pharmaceutical packaging under two categories with a gold, silver, and bronze award in each. The two categories will focus on design and processes that reduce the overall impact on the environment.
“Collaboration and innovation are essential to delivering the changes needed to make sustainability core to how pharmaceutical packaging is designed and used,” said Nazneen Rahman, founder and CEO of YewMaker, in a press release. “By announcing the winners of these new awards at the Connect in Pharma conference this September, we can bring a sharper focus on sustainability innovations in the pharmaceutical industry.”
“We are very excited to be partnering with YewMaker to host these important awards at Connect in Pharma in Geneva,” added Renan Joel, divisional director at Connect in Pharma, in the release. “Connect in Pharma is designed to focus on innovation and technology in the pharma and biotech community, and sustainable medicine packaging design is an important area of innovation in the sector. We are delighted to be coupling innovation with sustainability while putting the future of the planet in the spotlight.”
Source:
Advertisement
Related to this article
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
AAPS PharmSci 360 2026: E&L Standards Harmonization
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5